Clinical trial · Interventional
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer
A Pilot Study Evaluating Megestrol Acetate Modulation in Advanced Breast Cancer With Positive Hormonal Receptor
NCT03024580CI-TRIAL-00040082MEGAunknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This pilot trial evaluates in vivo megestrol acetate (MA) modulation of steroidal receptors in advanced breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasm | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anastrozole 1Mg Tablet | Drug | Anastrozole | ALIAS |
| Exemestane 25 MG | Drug | Exemestane | ALIAS |
| Fulvestrant 50Mg Solution for Injection | Drug | Fulvestrant | ALIAS |
| Letrozole 2.5Mg Tablet | Drug | Letrozole | ALIAS |
| Megestrol Acetate 160Mg Tablet | Drug | Megestrol | ALIAS |
| Tamoxifen 20Mg Tablet | Drug | Tamoxifen | ALIAS |
Design
Arms and outcomes
Arms (6)
- type
- EXPERIMENTAL
- label
- Megestrol acetate
- description
- Megestrol acetate 160 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
- interventionNames
- Drug: Megestrol Acetate 160Mg Tablet
- type
- ACTIVE_COMPARATOR
- label
- Anastrozole
- description
- Anastrozole 1 mg PO daily until disease progression or unacceptable toxicity Tumor biopsy and blood collection before treatment initiation and at the time of disease progression.
- interventionNames
- Drug: Anastrozole 1Mg Tablet
- type
- ACTIVE_COMPARATOR
- label
- Letrozole
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Metastatic breast cancer with ER and/or PR positive (primary tumor) * Metastatic site amenable to biopsy Exclusion Criteria: * Platelet count below 100,000 / mm3 * Renal or hepatic impairment * Coagulation disorder
References
Publications (0)
Data not yet available
No reference posted for this study.